Eltrombopag polpharma

Package leaflet: Information for the user

Eltrombopag Polpharma, 12.5 mg, film-coated tablets
Eltrombopag Polpharma, 25 mg, film-coated tablets
Eltrombopag Polpharma, 50 mg, film-coated tablets
Eltrombopag Polpharma, 75 mg, film-coated tablets
Eltrombopagum
Please read this leaflet carefully before taking this medicine because it contains important
information for you.

• Keep this leaflet. You may need to read it again.
• If you have any further questions, please ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
• If you experience any side effects, including any not listed in this leaflet, please inform your doctor or pharmacist. See section 4.

Leaflet contents:

1. What Eltrombopag Polpharma is and what it is used for
2. What you need to know before taking Eltrombopag Polpharma
3. How to take Eltrombopag Polpharma
4. Possible side effects
5. How to store Eltrombopag Polpharma
6. Contents of the pack and other information

1. What Eltrombopag Polpharma is and what it is used for

Eltrombopag Polpharma contains eltrombopag, which belongs to a group of medicines called thrombopoietin receptor agonists. This medicine is used to increase the number of platelets in your blood. Platelets are blood components that help reduce or prevent the risk of bleeding.

Eltrombopag Polpharma is used in the treatment of a blood clotting disorder called immune (primary) thrombocytopenia in patients over 1 year of age who have already been treated with other medicines (corticosteroids or immunoglobulins) that were ineffective. Immune thrombocytopenia is caused by a low number of blood platelets (thrombocytopenia). People with immune thrombocytopenia are at higher risk of bleeding. Symptoms that patients with immune thrombocytopenia may notice include petechiae (small, flat, red, round spots under the skin), bruising, nosebleeds, bleeding gums, and difficulty stopping bleeding after a cut or injury.

Eltrombopag Polpharma may also be used to treat low platelet counts (thrombocytopenia) in adults with hepatitis C virus (HCV) infection who have experienced difficulties due to side effects during interferon-based treatment. Many people with hepatitis C have low platelet counts, not only due to the disease itself but also as a result of certain antiviral medicines used in treatment. Taking Eltrombopag Polpharma may help patients complete a full course of antiviral therapy (pegylated interferon and ribavirin).

2. Important information before using Eltrombopag Polpharma

When not to use Eltrombopag Polpharma

• if the patient is allergic to eltrombopag or to any of the other ingredients of this medicine (listed in section 6 under "What Eltrombopag Polpharma contains"). The patient should consult a doctor if they think they are experiencing the condition described above.

Warnings and precautions
Before starting treatment with Eltrombopag Polpharma, discuss the following with your doctor:

• if the patient has liver disease. Patients with low platelet counts and/or advanced (chronic) liver disease are at increased risk of adverse reactions, including life-threatening liver damage and blood clots. If the doctor considers that the benefits of taking Eltrombopag Polpharma outweigh the risks, the patient will be closely monitored during treatment.
• if the patient is at risk of venous or arterial thrombosis, or if there is a family history of blood clots. The risk of thrombosis may be increased:
• if the patient is elderly
• if the patient has been immobilized for a prolonged period
• if the patient has a malignant tumour
• if the patient is taking oral contraceptives or hormone replacement therapy
• if the patient has recently undergone surgery or experienced trauma
• if the patient is overweight
• if the patient smokes
• if the patient has advanced chronic liver disease. The patient should inform the doctor before starting treatment if any of the above conditions apply. Eltrombopag Polpharma should not be taken unless the doctor considers that the expected benefits outweigh the risk of thrombosis.
• if the patient has cataracts (clouding of the eye's lens)
• if the patient has other blood disorders, such as myelodysplastic syndrome (MDS). Before starting Eltrombopag Polpharma, the doctor will perform tests to rule out this condition. If the patient has MDS and takes Eltrombopag Polpharma, MDS may worsen.

The patient should inform the doctor if any of the above situations apply.
Ophthalmological examination
The treating doctor will recommend regular check-ups to detect cataracts. If the patient does not routinely undergo ophthalmological examinations, the doctor should schedule regular eye exams. Examinations may also include detection of any bleeding in or near the retina (the light-sensitive layer at the back of the eye).
Regular monitoring is required
Before starting Eltrombopag Polpharma, the doctor will perform blood tests to assess blood cells, including platelets. These tests will be repeated periodically during treatment.
Liver function blood tests
Eltrombopag Polpharma may cause blood test results indicating liver damage—elevated activity of certain liver enzymes, particularly bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST). If the patient is receiving interferon-based therapy concurrently with Eltrombopag Polpharma for thrombocytopenia associated with hepatitis C, certain liver conditions may worsen.
Before starting Eltrombopag Polpharma and periodically during treatment, blood tests assessing liver function will be performed. It may be necessary to discontinue Eltrombopag Polpharma if levels of these substances rise too high or if other signs of liver damage occur.
Please refer to section 4 of this leaflet, “ Liver disorders ”.
Monitoring platelet count
If the patient stops taking Eltrombopag Polpharma, low platelet count may recur within a few days. Platelet counts will be monitored, and the treating doctor will discuss appropriate precautions with the patient.
A very high platelet count may increase the risk of thrombosis. However, blood clots may also occur even when platelet counts are normal or low. The treating doctor will adjust the dose of Eltrombopag Polpharma to avoid excessive increases in platelet count.
Seek immediate medical help if the patient experiences any of the following symptoms of thrombosis:

• swelling, pain, or tenderness in one leg
• sudden shortness of breath, especially with acute chest pain or rapid breathing
• abdominal pain, abdominal swelling, or blood in the stool.

Bone marrow examinations
In patients with bone marrow disorders, medicines such as Eltrombopag Polpharma may worsen these conditions. Changes in the bone marrow may manifest as abnormal blood test results. The treating doctor may recommend direct bone marrow examinations during treatment with Eltrombopag Polpharma.
Tests to detect gastrointestinal bleeding
If the patient is receiving interferon-based therapy concurrently with Eltrombopag Polpharma, they will be monitored for signs of bleeding from the stomach or intestines after stopping Eltrombopag Polpharma treatment.
Heart examinations
The treating doctor may consider it necessary to monitor the patient's heart during treatment with Eltrombopag Polpharma and may perform an electrocardiogram (ECG).
Elderly patients (65 years and older)
There is limited data on the use of Eltrombopag Polpharma in patients aged 65 years and older. Caution should be exercised when using Eltrombopag Polpharma in patients aged 65 years and older.
Children and adolescents
Eltrombopag Polpharma is not recommended for children under 1 year of age with immune thrombocytopenia. It is also not recommended for patients under 18 years of age with thrombocytopenia due to hepatitis C virus infection.
Eltrombopag Polpharma and other medicines
Inform your doctor or pharmacist about all medicines the patient is currently taking or has recently taken, as well as any medicines they plan to take. This includes over-the-counter medicines and vitamins.
Some commonly used medicines interact with Eltrombopag Polpharma – including both prescription and over-the-counter medicines, as well as mineral-containing supplements. These include:

• acid-reducing medicines used to treat indigestion, heartburn, stomach ulcers (see also "When to take the medicine" in section 3)
• medicines called statins, used to lower cholesterol levels
• certain medicines used to treat HIV infection, such as lopinavir and/or ritonavir
• cyclosporine, used in organ transplantation or in immunological disorders
• mineral products such as iron, calcium, magnesium, aluminium, selenium, and zinc, which may be components of vitamin and mineral supplements (see also "When to take the medicine" in section 3)
• medicines such as methotrexate and topotecan, used in the treatment of cancer.

Consult a doctor if the patient is taking any of the medicines listed above. Some of these should not be taken during treatment with Eltrombopag Polpharma; others may require dose adjustments or appropriate timing of administration. The treating doctor will review all medicines the patient is taking and recommend changes if necessary.
If the patient is taking anticoagulant medicines, the risk of bleeding may be increased. The treating doctor will discuss this with the patient.
If the patient is taking corticosteroids, danazol, and/or azathioprine, doses of these medicines may be reduced or their use discontinued during concomitant treatment with Eltrombopag Polpharma.
Taking Eltrombopag Polpharma with food and drink
Eltrombopag Polpharma must not be taken with dairy products or dairy-based beverages, as calcium in dairy products affects the absorption of the medicine. For further information, see "When to take the medicine" in section 3.
Pregnancy and breastfeeding
Do not use Eltrombopag Polpharma during pregnancy unless specifically advised by a doctor.
The effect of Eltrombopag Polpharma when used during pregnancy is unknown.

• Inform the doctor if the patient is pregnant, suspects she may be pregnant, or is planning a pregnancy.
• An effective method of contraception must be used during treatment with Eltrombopag Polpharma to prevent pregnancy.
• Inform the doctor if the patient becomes pregnant while taking Eltrombopag Polpharma.

Breastfeeding is not recommended during treatment with Eltrombopag Polpharma. It is not known whether Eltrombopag Polpharma passes into breast milk.
Inform the doctor if the patient is breastfeeding or planning to breastfeed.
Driving and operating machinery
Eltrombopag Polpharma may cause dizziness and other adverse effects that may impair attention.
Do not drive or operate machinery unless the patient is certain that these symptoms do not occur.
Eltrombopag Polpharma contains isomalt and sodium
If the patient has previously been diagnosed with intolerance to certain sugars, they should consult their doctor before taking this medicine.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, meaning it is considered "sodium-free".

3. How to use Eltrombopag Polpharma

This medicine should always be used exactly as prescribed by the doctor. If in doubt, consult a doctor or pharmacist. The dose or dosing regimen of Eltrombopag Polpharma must not be changed unless advised by a doctor or pharmacist. While taking Eltrombopag Polpharma, the patient will remain under the care of a physician experienced in managing the disease affecting the patient.

How much medicine to take

In primary immune thrombocytopenia

Adults and children (aged 6 to 17 years) – the usual starting dose in primary immune thrombocytopenia is one 50 mg tablet of Eltrombopag Polpharma once daily.
Patients of East or South-East Asian origin may require a lower starting dose of 25 mg.

Children (aged 1 to 5 years) – the usual starting dose in primary immune thrombocytopenia is one 25 mg tablet of Eltrombopag Polpharma once daily.

In chronic hepatitis C

Adults – the usual starting dose in chronic hepatitis C is one 25 mg tablet of Eltrombopag Polpharma once daily.
For patients of East or South-East Asian origin, treatment should be initiated at the same 25 mg dose.

The effect of Eltrombopag Polpharma may begin within 1 to 2 weeks. Depending on the patient's response to treatment with Eltrombopag Polpharma, the doctor may adjust the daily dose.

How to take the tablets

The tablets should be swallowed whole with water.

When to take the medicine

Make sure that

• 4 hours before
• and 2 hours after taking Eltrombopag Polpharma, the patient does not consume the following foods:
• dairy products, such as cheese, butter, yoghurt, ice cream
• milk or beverages containing milk, yoghurt, or cream
• antacids used to treat indigestion and heartburn
• vitamin and mineral supplements containing iron, calcium, magnesium, aluminium, selenium, or zinc.

Failure to follow these instructions may result in inadequate absorption of Eltrombopag Polpharma.

Consult a doctor for further information regarding suitable foods and drinks.

Taking more than the recommended dose of Eltrombopag Polpharma

Seek immediate advice from a doctor or pharmacist. If possible, show them the medicine packaging or this leaflet. The patient's condition will be monitored to detect any adverse reactions and initiate appropriate treatment promptly.

Missing a dose of Eltrombopag Polpharma

Take the next dose at the usual time. Do not take more than one dose of Eltrombopag Polpharma per day.

Stopping treatment with Eltrombopag Polpharma

Do not stop taking Eltrombopag Polpharma without consulting a doctor. If the doctor decides to discontinue treatment, the patient's platelet count will be monitored weekly for four weeks. See also "Bleeding or bruising after stopping treatment" in section 4.

If there are any further doubts about the use of this medicine, consult a doctor or pharmacist.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everyone will experience them.
Symptoms to be aware of: consult a doctor
Patients treated with Eltrombopag Polpharma for immune thrombocytopenia or low platelet count associated with hepatitis C may experience symptoms of severe adverse reactions. It is important to inform your doctor if any of these symptoms occur.
Increased risk of blood clots
Some patients may have an increased risk of blood clots, and medicines such as Eltrombopag Polpharma may increase this risk. Sudden blockage of a blood vessel by a clot is an uncommon adverse reaction and may occur in no more than 1 in 100 patients.
Seek immediate medical help if the patient experiences symptoms of a blood clot such as:

• swelling, pain, warmth, redness, or tenderness in one leg
• sudden shortness of breath, especially with sharp chest pain or rapid breathing
• abdominal (stomach) pain, abdominal swelling, blood in stool.

Liver problems
Eltrombopag Polpharma may cause changes detectable in blood tests, which may indicate liver damage. Liver disorders (increased liver enzyme activity in blood tests) are common and may affect no more than 1 in 10 patients. Other liver problems are uncommon and may affect no more than 1 in 100 patients.
If any of the following symptoms of liver problems occur:

• yellowing of the skin or whites of the eyes (jaundice)
• abnormally dark urine
  contact your doctor immediately.

Bleeding or bruising after stopping treatment
Usually within two weeks of stopping Eltrombopag Polpharma, the patient's platelet count decreases to the level observed before starting treatment with Eltrombopag Polpharma. A low platelet count may increase the risk of bleeding or bruising. Your doctor will monitor the patient's platelet count for at least 4 weeks after stopping Eltrombopag Polpharma.
Inform your doctor if bruising or bleeding occurs after stopping Eltrombopag Polpharma.
Some patients may experience gastrointestinal bleeding after discontinuing peginterferon, ribavirin, and Eltrombopag Polpharma. Symptoms include:

• black, tarry stools (stool discoloration is an uncommon adverse reaction, which may affect no more than 1 in 100 patients)
• blood in stool
• vomiting blood or coffee-ground-like material. Contact your doctor immediately if any of these symptoms occur.

The following adverse reactions have been reported as associated with eltrombopag treatment in adult patients with immune thrombocytopenia:
Very common adverse reactions (may occur in more than 1 in 10 patients):

• infection of the nose, sinuses, throat, and upper respiratory tract (upper respiratory tract infection)
• cough, common cold
• nausea, diarrhoea
• back pain.

Very common adverse reactions detectable in blood tests:

• increased liver enzyme activity (alanine aminotransferase (AlAT)).

Common adverse reactions (may occur in no more than 1 in 10 patients):

• influenza, herpes, pneumonia, irritation and inflammation (swelling) of sinuses, inflammation (swelling) and infection of tonsils, lung, sinus, nose and throat infection, gingivitis, sore throat and discomfort when swallowing
• loss of appetite
• sleep disturbances, depression
• reduced skin sensation, tingling, pricking or numbness commonly known as "pins and needles", drowsiness, migraine
• eye disorders, including abnormal eye test results, dry eyes, eye pain and blurred vision
• ear pain, sensation of spinning (dizziness)
• pain, swelling and tenderness in one leg (usually calf) with warm skin in the affected area (symptoms of deep vein thrombosis), localized swelling filled with blood from a damaged blood vessel (haematoma), hot flushes
• watery nasal discharge
• oral disorders, including dry mouth, mouth pain, tongue sensitivity, bleeding gums, mouth ulcers, toothache, vomiting, abdominal pain, bloating/gas
• abnormal liver function
• skin changes including: excessive sweating, raised itchy rash, red spots, changes in skin appearance, hair loss
• muscle pain, muscle cramps, muscle weakness, bone pain
• passing foamy urine with presence of air bubbles (symptoms of protein in urine)
• heavy menstrual bleeding
• high body temperature, feeling of warmth, chest pain, feeling of weakness.

Common adverse reactions detectable in blood tests:

• decreased number of red blood cells (anaemia), decreased platelet count (thrombocytopenia), decreased number of white blood cells, decreased haemoglobin concentration, increased eosinophil count, increased number of white blood cells (leukocytosis)
• increased uric acid concentration, decreased potassium concentration
• increased liver enzyme activity (aspartate aminotransferase (AspAT))
• increased blood bilirubin concentration (a substance produced by the liver)
• increased concentration of certain proteins, increased creatinine concentration
• increased alkaline phosphatase concentration.

Uncommon adverse reactions (may occur in no more than 1 in 100 patients):

• skin infection
• rectal and colon cancer
• allergic reaction
• loss of appetite, painful joint swelling due to uric acid (gout)
• lack of interest, mood changes, crying that is difficult to control or occurs unexpectedly
• problems with balance, speech and nerve function, tremor, paralysis on one side of the body, migraine with aura, nerve damage, dilation or swelling of blood vessels causing headache
• eye disorders, including increased tear production, clouding of the lens in the eye (cataract), retinal haemorrhage, dry eyes
• rapid heartbeat, irregular heartbeat, bluish skin colouration, heart rhythm disorders (QT interval prolongation), which may indicate heart and blood vessel problems, interruption of blood flow to part of the heart
• pain, swelling and (or) redness around a vein, which may indicate blood clot in a vein, blood clot, redness
• sudden shortness of breath, especially with accompanying sharp chest pain and (or) rapid breathing, which may indicate blood clots in the lungs (see "Increased risk of blood clots" above in section 4), loss of function of part of the lung due to blockage of the pulmonary artery, disorders of the nose, throat and sinuses, breathing disorders during sleep
• oral disorders, including dry or painful mouth, tongue pain, bleeding gums, oral discomfort, blisters/ulcers in the mouth and throat, gastrointestinal disorders, including frequent bowel movements, food poisoning, blood in stool, bloody vomiting, rectal bleeding, stool colour changes, abdominal bloating, constipation
• yellowing of the skin and (or) abdominal pain, which may indicate biliary obstruction, liver damage, inflammatory liver damage (see "Liver disorders" above in section 4), drug-induced liver injury
• painful or unusual skin sensations, skin changes including skin discolouration, peeling, redness, itching and sweating, cold sweats
• muscle weakness
• kidney disorders, including kidney inflammation, excessive urination at night, kidney failure, white blood cells in urine
• feeling of warmth, restlessness, bleeding around catheter (if present) into the skin, redness or swelling around wound, general malaise, foreign body sensation
• sunburn.

Uncommon adverse reactions detectable in laboratory tests:

• changes in shape of red blood cells, decreased number of red blood cells (anaemia) due to excessive destruction of red blood cells (haemolytic anaemia), increased myelocytes, increased band neutrophils, presence of developing white blood cells, which may indicate certain diseases, increased platelet count, elevated haemoglobin level
• decreased calcium concentration
• increased blood urea concentration, increased protein in urine
• increased albumin concentration in blood, increased total protein concentration, decreased albumin concentration in blood, increased urine pH.

The following additional adverse reactions have been reported as associated with eltrombopag treatment in children (aged 1 to 17 years) with ITP:
If these adverse reactions worsen, inform your doctor, pharmacist, or nurse.
Very common adverse reactions (may occur in more than 1 in 10 children):

• infection of the nose, sinuses, throat and upper respiratory tract, common cold (upper respiratory tract infection)
• cough
• nausea, diarrhoea, abdominal pain
• high body temperature.

Common adverse reactions (may occur in no more than 1 in 10 children):

• difficulty falling asleep (insomnia)
• itching, runny or stuffy nose, sore throat, cold, nasal mucosal congestion and sneezing, nasal and throat pain
• toothache, oral problems, including dry mouth, mouth pain, tongue sensitivity, bleeding gums, mouth ulcers.

The following adverse reactions have been reported as associated with eltrombopag treatment in combination with peginterferon and ribavirin in patients with hepatitis C:
Very common adverse reactions (may occur in more than 1 in 10 patients):

• loss of appetite
• headache
• cough
• nausea, diarrhoea
• itching, swelling of hands or feet, unusual hair loss
• muscle pain, muscle weakness
• fever, feeling of fatigue, flu-like illness, weakness, chills.

Very common adverse reactions detectable in blood tests:

• decreased number of red blood cells (anaemia).

Common adverse reactions (may occur in no more than 1 in 10 patients):

• urinary tract infections, infection of the nose, sinuses, throat and upper respiratory tract, common cold (upper respiratory tract infection), bronchial mucosa inflammation, nasal passage, throat and oral cavity inflammation, flu-like symptoms, dry mouth, oral pain or inflammation, toothache, influenza, cold sores
• weight loss
• sleep disorders, abnormal drowsiness, depression, anxiety
• dizziness, concentration and memory problems, mood changes, brain dysfunction due to liver damage, tingling or numbness in hands or feet
• vision disorders, including: clouding of the eye lens (cataract), dry eye syndrome, small yellow deposits on the retina, yellowing of the whites of the eyes, retinal haemorrhage
• sensation of spinning (dizziness)
• rapid or irregular heartbeat (palpitations)
• shortness of breath, cough with sputum, runny nose, sore throat and discomfort when swallowing
• gastrointestinal disorders including: vomiting, abdominal pain, indigestion, constipation, abdominal bloating, taste disturbances, haemorrhoids, stomach pain or discomfort, swelling and bleeding of blood vessels in the oesophagus, toothache
• liver problems including liver tumour, yellowing of the whites of the eyes or skin (jaundice), drug-induced liver injury (see above "Liver disorders" in section 4)
• skin changes including: rash, dry skin, skin eruptions, skin redness, itching, excessive sweating, skin growths, hair loss
• joint pain, back pain, bone pain, limb pain (legs, arms, hands or feet), muscle cramps
• irritability, general malaise, skin reaction such as redness or swelling and pain at injection site, chest pain and discomfort, fluid accumulation in the body or limbs causing swelling
• depression, anxiety, sleep disorders, nervousness
• fever, headache.

Common adverse reactions detectable in blood tests:

• increased blood sugar (glucose) concentration, decreased number of white blood cells, decreased number of neutrophils, decreased blood albumin concentration, decreased haemoglobin concentration, increased blood bilirubin concentration (a substance produced in the liver), changes in enzymes controlling blood coagulation.

Uncommon adverse reactions (may occur in no more than 1 in 100 patients):

• stomach flu (gastroenteritis), sore throat
• decreased number of red blood cells (anaemia) due to excessive destruction of red blood cells (haemolytic anaemia)
• disorientation, agitation
• blisters or ulcers in the mouth, gastritis
• blood clots in the vein leading blood to the liver (possible liver and (or) gastrointestinal damage), liver failure
• skin changes including discolouration, peeling, redness, itching, skin lesions and night sweats
• abnormal blood clotting in small blood vessels with kidney failure, painful urination
• rash, bruising at injection sites, chest discomfort
• heart rhythm disorders (QT interval prolongation).

Reporting of adverse reactions
If any adverse reactions occur, including any not listed in this leaflet, inform your doctor, pharmacist, or nurse. Adverse reactions can be reported directly to the Department of Monitoring Adverse Drug Reactions, Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Tel.: +48 22 4921301
Fax: +48 22 4921309
Website: https://smz.ezdrowie.gov.pl
Adverse reactions can also be reported to the marketing authorisation holder.
Reporting adverse reactions helps provide more information on the safety of this medicine.

5. How to store Eltrombopag Polpharma

Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and blister marked as EXP.
The expiry date refers to the last day of the stated month.
The packaging label shows EXP followed by the expiry date and Lot followed by the batch number.
No special storage conditions are required for this medicine.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and other information

What Eltrombopag Polpharma contains

• The active substance is eltrombopag olamine. Eltrombopag Polpharma 12.5 mg: each film-coated tablet contains eltrombopag olamine equivalent to 12.5 mg of eltrombopag. Eltrombopag Polpharma 25 mg: each film-coated tablet contains eltrombopag olamine equivalent to 25 mg of eltrombopag. Eltrombopag Polpharma 50 mg: each film-coated tablet contains eltrombopag olamine equivalent to 50 mg of eltrombopag. Eltrombopag Polpharma 75 mg: each film-coated tablet contains eltrombopag olamine equivalent to 75 mg of eltrombopag.
• Other ingredients: microcrystalline cellulose, mannitol, povidone, isomalt (E 953), calcium silicate, sodium carboxymethyl starch (type A), magnesium stearate (tablet core); hypromellose, titanium dioxide (E 171), iron oxide red (E 172), iron oxide yellow (E 172) (only in 12.5 mg, 25 mg and 50 mg tablets), triacetin (tablet coating).

What Eltrombopag Polpharma looks like and contents of the pack
Eltrombopag Polpharma 12.5 mg are orange to brown, round, biconvex film-coated tablets with an imprint “I” on one side and a diameter of approximately 5.5 mm.
Eltrombopag Polpharma 25 mg are dark pink, round, biconvex film-coated tablets with an imprint “II” on one side and a diameter of approximately 8 mm.
Eltrombopag Polpharma 50 mg are pink, round, biconvex film-coated tablets with an imprint “III” on one side and a diameter of approximately 10 mm.
Eltrombopag Polpharma 75 mg are red to brown, round, biconvex film-coated tablets with an imprint “IV” on one side and a diameter of approximately 12 mm.
Eltrombopag Polpharma 12.5 mg is available in cardboard boxes containing 10, 14, 28, 30 or 84 film-coated tablets packed in blisters, or in cardboard boxes containing 10x1, 14x1, 28x1, 30x1 or 84x1 film-coated tablets packed in perforated single-dose blisters.
Eltrombopag Polpharma 25 mg is available in cardboard boxes containing 10, 14, 28, 30 or 84 film-coated tablets packed in blisters, or in cardboard boxes containing 10x1, 14x1, 28x1, 30x1 or 84x1 film-coated tablets packed in perforated single-dose blisters.
Eltrombopag Polpharma 50 mg is available in cardboard boxes containing 10, 14, 28, 30 or 84 film-coated tablets packed in blisters, or in cardboard boxes containing 10x1, 14x1, 28x1, 30x1 or 84x1 film-coated tablets packed in perforated single-dose blisters.
Eltrombopag Polpharma 75 mg is available in cardboard boxes containing 10, 14, 28, 30 or 84 film-coated tablets packed in blisters, or in cardboard boxes containing 10x1, 14x1, 28x1, 30x1 or 84x1 film-coated tablets packed in perforated single-dose blisters.
Not all pack sizes may be marketed.

Marketing Authorisation Holder
Zakłady Farmaceutyczne POLPHARMA S.A.
ul. Pelplińska 19, 83-200 Starogard Gdański
tel. +48 22 364 61 01

Manufacturer
Synthon Hispania S.L.
Calle De Castello 1
08330 Sant Boi De Llobregat
Spain
Synthon B.V.
Microweg 22
6545 CM Nijmegen
The Netherlands